Studies of the inhibition of C56-initiated lysis (reactive lysis). IV. Antagonism of the inhibitory activity c567-INH by poly-L-lysine.
The stable intermediate complex C56 can initiate the lysis (reactive lysis) of unsensitized erythrocytes (E) by the membrane attack machanism of complement. Certain serum constituents designated C567-INH inhibit reactive lysis by preventing the C567 complex, once formed, from attaching to a membrane surface. It is shown here that microgram quantities of poly-L-lysine (PLL), a synthetic polycation of molecular weight 180,000, can reverse the effests of C567-INH, and thereby potentiate formation of EC567 by erythrocytes, C56 and C7 in whole serum. Erythrocytes exposed to PLL in a preincubation step did not show either increased susceptibility to C567 or resistance to C567-INH, and reversal of C567-IHN by given amounts of PLL was not diminished as cell concentrations were greatly increased, indicating that the effect of PLL was predominantly directed against fluid phase rather than against erythrocyte membrane substrates. The effects of PLL and C567-INH were quantitatively reciprocal. Thus, PLL-induced potentiation of C56-induced lysis is a solute effect which seems to involve direct neutralization of naturally occurring serum inhibitors of the C567 trimolecular complex of complement. The use of PLL thus provides a suitable antagonist for C567-INH in reaction mixtures, and allows evaluation of the role of C567 and C567-INH in a variety of situations involving C-mediated lysis.
D000510:Alpha-Globulins / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D000818:Animals; D001769:Blood; D002452:Cell Count; D002462:Cell Membrane; D003182:Complement C5 / Q000037:antagonists & inhibitors; D003183:Complement C6 / Q000037:antagonists & inhibitors; D003184:Complement C7 / Q000037:antagonists & inhibitors; D003169:Complement Inactivator Proteins; D004305:Dose-Response Relationship, Drug; D004912:Erythrocytes / Q000187:drug effects / Q000276:immunology; D006168:Guinea Pigs / Q000276:immunology; D006384:Hemagglutination / Q000187:drug effects; D006461:Hemolysis; D006801:Humans; D008239:Lysine / Q000494:pharmacology; D010455:Peptides / Q000494:pharmacology*; D012756:Sheep / Q000276:immunology
D000510:Alpha-Globulins; D003182:Complement C5; D003183:Complement C6; D003184:Complement C7; D003169:Complement Inactivator Proteins; D010455:Peptides; D008239:Lysine